pharma · Birch Pollen-induced Allergic Rhinoconjunctivitis
Allergon AB
Allergen
Allergen is a pharma organization headquartered in JP. Primary therapeutic focus areas include Birch Pollen-induced Allergic Rhinoconjunctivitis. NovaPharmaNews links 1 clinical program(s), 3 drug profile(s), and 0 paten
SE HQ
23 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- SE
- Employees
- 23
- Programs
- 1
- Drugs
- 6
- Patents
- 24
YOBI/SL79.22
Phase 3 · small molecule · Birch Pollen-induced Allergic Rhinoconjunctivitis
YOBI/SL79.22 for Birch Pollen-induced Allergic Rhinoconjunctivitis is a Phase 3 program (small_molecule) at Allergen with 1 ClinicalTrials.gov record(s).
Internal code YOBI/SL79.22
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Allergen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Birch Pollen-induced Allergic Rhinoconjunctivitis
- Status
- active
- Trials
- 1